The dates of the sales are as recent as March 2021
Insider Transaction Type Value Date Shares
ANDRES JUAN
Chief Technology Officer Sale at price 133.24 per share. Direct 666,200 Mar 10, 2021 5,000
ANDRES JUAN
Chief Technology Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 61,050 Mar 10, 2021 5,000
HENDERSON LORI M
General Counsel Sale at price 127.11 per share. Direct 838,926 Mar 09, 2021 6,600
HENDERSON LORI M
General Counsel Conversion of Exercise of derivative security at price 25.93 per share. Direct 171,138 Mar 09, 2021 6,600
ZAKS TAL ZVI
Officer Sale at price 123.48 - 132.91 per share. Direct 2,118,863 Mar 08, 2021 16,478
ZAKS TAL ZVI
Officer Conversion of Exercise of derivative security at price 12.21 - 20.93 per share. Direct 298,446 Mar 08, 2021 16,478
ANDRES JUAN
Officer Sale at price 129.41 per share. Direct 647,050 Mar 08, 2021 5,000
ANDRES JUAN
Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 61,050 Mar 08, 2021 5,000
BANCEL STEPHANE J
Chief Executive Officer Sale at price 122.10 - 133.50 per share. Indirect 1,415,858 Mar 05, 2021 11,046
HENDERSON LORI M
General Counsel Sale at price 128.58 per share. Direct 848,628 Mar 04, 2021 6,600
HENDERSON LORI M
General Counsel Conversion of Exercise of derivative security at price 25.93 per share. Direct 171,138 Mar 04, 2021 6,600
BANCEL STEPHANE J
Chief Executive Officer Sale at price 128.58 - 145.60 per share. Indirect 2,596,200 Mar 04, 2021 19,000
BANCEL STEPHANE J
Chief Executive Officer Stock Gift at price 0.00 per share. Direct 0 Mar 03, 2021 2,000
HOGE STEPHEN
President Sale at price 145.60 - 153.77 per share. Direct 2,993,700 Mar 03, 2021 20,000
HOGE STEPHEN
President Conversion of Exercise of derivative security at price 0.99 per share. Direct 19,800 Mar 03, 2021 20,000
ANDRES JUAN
Chief Technology Officer Sale at price 145.60 per share. Direct 728,000 Mar 03, 2021 5,000
ANDRES JUAN
Chief Technology Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 61,050 Mar 03, 2021 5,000
HENDERSON LORI M
General Counsel Sale at price 153.77 per share. Direct 1,014,882 Mar 02, 2021 6,600
HENDERSON LORI M
General Counsel Conversion of Exercise of derivative security at price 25.93 per share. Direct 171,138 Mar 02, 2021 6,600
ZAKS TAL ZVI
Officer Sale at price 146.68 - 157.29 per share. Direct 1,504,518 Mar 01, 2021 10,000
ZAKS TAL ZVI
Officer Conversion of Exercise of derivative security at price 12.21 - 14.22 per share. Direct 132,150 Mar 01, 2021 10,000
ANDRES JUAN
Chief Technology Officer Sale at price 153.84 per share. Direct 769,200 Mar 01, 2021 5,000
ANDRES JUAN
Chief Technology Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 61,050 Mar 01, 2021 5,000
BANCEL STEPHANE J
Chief Executive Officer Sale at price 151.67 - 159.59 per share. Indirect 1,708,845 Feb 26, 2021 11,046
BANCEL STEPHANE J
Chief Executive Officer Sale at price 150.41 - 150.89 per share. Indirect 2,862,590 Feb 25, 2021 19,000
AFEYAN NOUBAR BOGHOS
Director Sale at price 144.17 - 150.41 per share. Indirect 256,378,924 Feb 24, 2021 1,753,697
BANCEL STEPHANE J
Chief Executive Officer Stock Gift at price 0.00 per share. Direct 0 Feb 24, 2021 1,000
HOGE STEPHEN
President Sale at price 136.83 - 150.62 per share. Direct 2,958,323 Feb 24, 2021 20,000
AFEYAN NOUBAR BOGHOS
Director Sale at price 136.48 - 170.03 per share. Indirect 730,069,590 Feb 23, 2021 4,784,404
HOGE STEPHEN
President Conversion of Exercise of derivative security at price 0.99 per share. Direct 9,900 Feb 23, 2021 10,000
ZAKS TAL ZVI
Officer Sale at price 159.32 - 169.81 per share. Direct 824,196 Feb 22, 2021 5,000
ZAKS TAL ZVI
Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 61,050 Feb 22, 2021 5,000
ANDRES JUAN
Chief Technology Officer Sale at price 166.63 per share. Direct 833,150 Feb 22, 2021 5,000
ANDRES JUAN
Chief Technology Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 61,050 Feb 22, 2021 5,000
BANCEL STEPHANE J
Chief Executive Officer Sale at price 171.64 - 178.91 per share. Indirect 1,930,893 Feb 19, 2021 11,046
BANCEL STEPHANE J
Chief Executive Officer Sale at price 171.80 - 174.28 per share. Indirect 3,286,520 Feb 18, 2021 19,000
BANCEL STEPHANE J
Chief Executive Officer Stock Gift at price 0.00 per share. Direct 0 Feb 17, 2021 1,000
HOGE STEPHEN
President Sale at price 182.80 per share. Direct 2,742,000 Feb 16, 2021 15,000
HOGE STEPHEN
President Conversion of Exercise of derivative security at price 0.99 per share. Direct 9,900 Feb 16, 2021 10,000
ANDRES JUAN
Chief Technology Officer Sale at price 182.80 per share. Direct 914,000 Feb 16, 2021 5,000
ANDRES JUAN
Chief Technology Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 61,050 Feb 16, 2021 5,000
BANCEL STEPHANE J
Chief Executive Officer Sale at price 178.47 - 183.80 per share. Indirect 2,010,106 Feb 12, 2021 11,046
HOGE STEPHEN
President Sale at price 185.00 per share. Direct 925,000 Feb 12, 2021 5,000
BANCEL STEPHANE J
Chief Executive Officer Sale at price 178.29 per share. Indirect 1,782,900 Feb 11, 2021 10,000
BANCEL STEPHANE J
Chief Executive Officer Stock Gift at price 0.00 per share. Direct 0 Feb 10, 2021 1,000
BANCEL STEPHANE J
Chief Executive Officer Sale at price 182.74 per share. Direct 1,644,660 Feb 10, 2021 9,000
ZAKS TAL ZVI
Officer Sale at price 178.20 - 186.84 per share. Direct 677,319 Feb 08, 2021 3,670
ZAKS TAL ZVI
Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 44,811 Feb 08, 2021 3,670
ANDRES JUAN
Chief Technology Officer Sale at price 176.98 per share. Direct 884,900 Feb 08, 2021 5,000
ANDRES JUAN
Chief Technology Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 61,050 Feb 08, 2021 5,000
BANCEL STEPHANE J
Chief Executive Officer Sale at price 171.48 - 176.69 per share. Indirect 1,928,751 Feb 05, 2021 11,046
BANCEL STEPHANE J
Chief Executive Officer Sale at price 156.51 - 166.42 per share. Indirect 3,072,790 Feb 04, 2021 19,000
BANCEL STEPHANE J
Chief Executive Officer Stock Gift at price 0.00 per share. Direct 0 Feb 03, 2021 1,000
HOGE STEPHEN
President Sale at price 156.51 - 158.40 per share. Direct 3,149,100 Feb 03, 2021 20,000
HOGE STEPHEN
President Conversion of Exercise of derivative security at price 0.99 per share. Direct 19,800 Feb 03, 2021 20,000
ZAKS TAL ZVI
Officer Sale at price 156.16 - 174.00 per share. Direct 811,696 Feb 01, 2021 5,000
ZAKS TAL ZVI
Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 61,050 Feb 01, 2021 5,000
ANDRES JUAN
Chief Technology Officer Sale at price 172.99 per share. Direct 864,950 Feb 01, 2021 5,000
ANDRES JUAN
Chief Technology Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 61,050 Feb 01, 2021 5,000
BANCEL STEPHANE J
Chief Executive Officer Sale at price 167.51 - 183.84 per share. Indirect 1,913,687 Jan 29, 2021 11,046
BANCEL STEPHANE J
Chief Executive Officer Sale at price 151.27 - 154.11 per share. Indirect 2,902,530 Jan 28, 2021 19,000
BANCEL STEPHANE J
Chief Executive Officer Stock Gift at price 0.00 per share. Direct 0 Jan 27, 2021 1,000
ZAKS TAL ZVI
Officer Sale at price 138.24 - 146.65 per share. Direct 715,578 Jan 25, 2021 5,000
ZAKS TAL ZVI
Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 61,050 Jan 25, 2021 5,000
HOGE STEPHEN
President Sale at price 138.79 - 146.83 per share. Direct 2,819,407 Jan 25, 2021 20,000
HOGE STEPHEN
President Conversion of Exercise of derivative security at price 0.99 per share. Direct 9,900 Jan 25, 2021 10,000
ANDRES JUAN
Chief Technology Officer Sale at price 138.77 per share. Direct 693,850 Jan 25, 2021 5,000
ANDRES JUAN
Chief Technology Officer Conversion of Exercise of derivative security at price 12.21 per share. Direct 61,050 Jan 25, 2021 5,000
BANCEL STEPHANE J
Chief Executive Officer Sale at price 129.59 - 134.70 per share. Indirect 1,455,983 Jan 22, 2021 11,046
BANCEL STEPHANE J
Chief Executive Officer Sale at price 124.51 - 125.28 per share. Indirect
Recent JNJ News
- Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt • Business Wire • 09/20/2024 10:53:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:19:26 PM
- Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims • Business Wire • 09/20/2024 07:43:00 PM
- RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer • PR Newswire (US) • 09/19/2024 10:54:00 PM
- Microsoft Boosts Share Buyback, Raises Dividends by 10%, Intel Secures Chip Deal with Amazon • IH Market News • 09/17/2024 10:40:35 AM
- Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer • PR Newswire (US) • 09/16/2024 06:50:00 AM
- New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer • PR Newswire (US) • 09/15/2024 06:30:00 AM
- RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer • PR Newswire (US) • 09/14/2024 01:45:00 PM
- RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer • PR Newswire (US) • 09/14/2024 07:10:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:44:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:43:45 PM
- TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease • PR Newswire (US) • 09/11/2024 10:22:00 PM
- Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw) • PR Newswire (US) • 09/10/2024 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 08:26:10 PM
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer • PR Newswire (US) • 09/08/2024 05:47:00 PM
- Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results • Business Wire • 09/05/2024 08:30:00 PM
- Qualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual Listing • IH Market News • 09/05/2024 10:11:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:48:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 07:51:09 PM
- Form N-PX - Annual Report of proxy voting record of management investment companies • Edgar (US Regulatory) • 08/29/2024 06:05:30 PM
- Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis • PR Newswire (US) • 08/29/2024 12:00:00 PM
- Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress • PR Newswire (US) • 08/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:26:20 PM
- IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts • IH Market News • 08/26/2024 12:58:21 PM
- Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024 • Business Wire • 08/26/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM